Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 34,501 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the sale, the chief executive officer owned 23,337 shares of the company’s stock, valued at $699,643.26. This represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

Shares of MAZE opened at $31.26 on Friday. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The stock has a market cap of $1.73 billion, a P/E ratio of -12.36 and a beta of 2.14. The stock’s 50-day moving average price is $25.92 and its two-hundred day moving average price is $35.67. Maze Therapeutics, Inc. has a 1 year low of $10.98 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. On average, equities analysts predict that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analyst Weigh In

MAZE has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Truist Financial cut their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics during the fourth quarter worth $39,000. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the fourth quarter worth $43,000. California State Teachers Retirement System lifted its stake in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after acquiring an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.